|
NIDA Research Monograph, Number 9 [Printed in 1976]
This monograph is not available by chapter. The Table of Contents (below) is shown to assist in locating information prior to downloading the monograph.
Download Monograph 9 - Narcotic Antagonists: Naltrexone (2.4 MB PDF format)
FOREWORD-----v
Jerome Jaffe
INTRODUCTION-----1
Pierre Renault, M.D.
THE FEDERAL ROLE IN NALTREXONE DEVELOPMENT
NIDA'S NALTREXONE RESEARCH PROGRAM-----5
Demetrios Julius, M.D.
REQUIREMENTS FOR DRUG DEVELOPMENT-----12
Edward C. Tocus, Ph.D.
PRECLINICAL TOXICITY STUDIES OF NALTREXONE-----16
Monique C. Braude, Ph.D. and J. Michael Morrison, M.S.
THE EFFECTS OF NALTREXONE IN THE CHRONIC SPINAL DOG AND ACUTE SPINAL CAT; POSSIBLE INTERACTION WITH NATURALLY - OCCURRING MORPHINE-LIKE ANTAGONISTS-----27
William Martin, M.D., James Bell, Ph.D., Paul Gilbert, Ph.D., Jewell Sloan, B.S., James Thompson
THE DEVELOPMENT OF SUSTAINED ACTION PREPARATIONS OF NARCOTIC ANTAGONISTS-----31
Robert E. Willette, Ph.D.
THE NAS DOUBLE-BLIND STUDY
EVOLUTION OF THE NATIONAL ACADEMY OF SCIENCES STUDY OF NALTREXONE-----37
Samuel C. Kaim, M.D.
PHILOSOPHY AND STATUS OF THE NAS CENA STUDIES-----45
Leo E. Hollister, M.D.
VARYING CLINICAL CONTEXTS FOR ADMINISTERING NALTREXONE-----48
Marc Hurzeler, M.D., David Gewirtz, M.S., Herbert Kleber, M.D.
PATIENT RESPONSE TO NALTREXONE: ISSUES OF ACCEPTANCE, TREATMENT EFFECTS AND FREQUENCY OF ADMINISTRATION-----67
Stephen Curran, M.A., and Charles Savage, M.D.
NALTREXONE IN METHANE MAINTENANCE PATIENTS ELECTING TO BECOME "DRUG FREE"-----70
Neil Haas, M.D., Walter Ling, M.D., Elaine Holmes, Ph.D., Mara Blakis, M.D.,
Margaret Litaker, MSW
COMMENTS AND FINDINGS FROM A NALTREXONE DOUBLE-BLIND STUDY-----74
John Keegan, M.A., Carol Lavenduski, A.C.S.W., Kenneth Schoof, M.D.
FACTORS INFLUENCING SUCCESS IN AN ANTAGONIST TREATMENT PROGRAM-----77
Sadashiv Parwatikar, M.D., FRCP (C), James Crawford, M.S., John V. Nelkupa,
Chona DeGracia, M.D.
THE NIDA CLINICAL STUDIES
A POINT OF VIEW CONCERNING TREATMENT APPROACHES WITH NARCOTIC ANTAGONISTS-----84
Richard B. Resnick, M.D., and Elaine Schuyten-Resnick, M.S.W.
CLINICAL EXPERIENCE WITH NALTREXONE IN 370 DETOXIFIED ADDICTS-----88
Muriel Thomas R.N., Frank Kauders, M.D., Marcel Harris, Judy Cooperstein, R.N., Gordon Hough, Ph.D., Richard Resnick, M.D.
NARCOTIC ANTAGONIST TREATMENT OF THE CRIMINAL JUSTICE PATIENT - INSTITUTIONAL VS OUTPATIENT - INCLUDING A 24-HOUR DETOX NALTREXONE INDUCTION REGIMEN WITH ORAL MEDICATION-----93
Leonard Brahen, Ph.D., M.D., Victoria Wiechert, MPS, Thomas Capone, Ph.D.
USE OF NARCOTIC ANTAGONISTS (NALTREXONE) IN AN ADDICTION TREATMENT PROGRAM-----99
David Lewis, M.D., Ronald Hersch, Ph.D., Rebecca Black, Ph.D., Joseph Mayer, Ph.D.
AN ANALYSIS OF NALTREXONE USE - ITS EFFICACY, SAFETY AND POTENTIAL-----106
Ralph Landsberg, D.O., Zebulon Taintor, M.D., Marjorie Plumb, Ph.D. Leonard Amico, B.A., Nancy Wicks, B.S.
CLINICAL EFFICACY OF NALTREXONE: A ONE YEAR FOLLOW-UP-----114
Richard Resnick, M.D., Michael Aronoff, M.D., Greta Lonborg, M.A.,
Richard Kestenbaum, Ph.D., Frank Kauders, M.D., Arnold Washton, Ph.D.
Gordon Hough, Ph.D.
THE NIDA BEHAVIORAL STUDIES
THE THEORETICAL BASIS OF NARCOTIC ADDICTION TREATMENT WITH NARCOTIC ANTAGONISTS-----120
Abraham Wikler, M.D.
LIMITATIONS OF AN EXTINCTION APPROACH TO NARCOTIC ANTAGONIST TREATMENT-----123
Roger E. Meyer, M.D., Mary Randall, M.S., Cecily Barrington, B.A., Steven M. Mirin, M.D., Isaac Greenberg, Ph.D.
NALTREXONE IN A BEHAVIORAL TREATMENT PROGRAM-----136
Charles P. O'Brien, M.D., Ph.D., and Robert Greenstein, M.D.
CLINICAL EXPERIENCE WITH NALTREXONE IN A BEHAVIORAL RESEARCH STUDY-----141
Robert Greenstein, M.D., Charles O'Brien, M.D., Ph.D., Jim Mintz, Ph.D.,
George E. Woody, M.D., Nancy Hanna, B.A.
COMPARISON OF TWO NALTREXONE TREATMENT PROGRAMS: NALTREXONE ALONE VERSUS NALTREXONE PLUS BEHAVIOR THERAPY-----150
Edward Callahan, Ph.D., Richard Rawson, Ph.D., Michael Glazer, M.A., Beverly McCleave, B.A., Richard Arias, B.A.
NALTREXONE IN THE MANAGEMENT OF HEROIN ADDICTION: CRITIQUE OF THE RATIONALE-----158
Avram Goldstein, M.D.
CURRENT STATUS OF NALTREXONE SAFETY DATA
INTERIM REPORT ON CLINIC INTAKE AND SAFETY DATA COLLECTED FROM 17 NIDA-FUNDED NALTREXONE STUDIES-----163
H. Alex Bradford; M.S., Frank L. Hurley, Ph.D., Oksana Golondzowski,
Catharine Dorrier
AGENDA - NAS - NIDA SATELLITE CONFERENCE ON NALTREXONE-----172
NALTREXONE BIBLIOGRAPHY-----176
|
|
|
